Join the THRIVE Clinical Study
Help develop potential new treatments for Thyroid Eye Disease
Find a THRIVE study site near me
The THRIVE Clinical Study
THRIVE is an ongoing Phase 3 clinical study of VRDN-001 as a potential treatment for people who have been diagnosed with moderate to severe active TED within the past 15 months.
In THRIVE, a trained professional administers the study drug by infusion through a vein in your arm.
Am I eligible to participate in THRIVE?
THRIVE participants must meet certain requirements, referred to as eligibility criteria, and be available to receive the necessary treatments.
Who can I contact for more information?
To learn more about THRIVE, please contact your doctor or your preferred study site directly.
For additional information about THRIVE or about the study sponsor, Viridian Therapeutics, please email patientadvocacy@viridiantherapeutics.com